Atlas Trials

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Clinical trial NCT05059236 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05059236
Sponsor
Bayer
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Hormone-sensitive Prostate Cancer
Start date
2021-11-04
Primary completion
2025-05-30
Enrollment
223

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.